Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings

about

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).

P2860

Q47111016-BA962517-1E3C-4231-A3CE-A39B7A388843 Q50045537-B0DF5CA7-A3D3-476E-9E6D-4E74AF76ED8F

P2860

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings

Item

http://www.wikidata.org/entity/Q26774097

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Eribulin in the Management of ...... s of Current Research Findings

@ast

Eribulin in the Management of ...... s of Current Research Findings

@en

Eribulin in the Management of ...... s of Current Research Findings

@nl

type

Item

label

Eribulin in the Management of ...... s of Current Research Findings

@ast

Eribulin in the Management of ...... s of Current Research Findings

@en

Eribulin in the Management of ...... s of Current Research Findings

@nl

prefLabel

Eribulin in the Management of ...... s of Current Research Findings

@ast

Eribulin in the Management of ...... s of Current Research Findings

@en

Eribulin in the Management of ...... s of Current Research Findings

@nl

P1476

Eribulin in the Management of ...... s of Current Research Findings

@en

P2093

Victor C Kok

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.

Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.

Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp.

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

P304

109-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/BCBCR.S32787

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Victor C. Kok

P577

2015-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286931473

http://www.w3.org/2001/XMLSchema#string

P698

26691012

http://www.w3.org/2001/XMLSchema#string

P932

4681420

http://www.w3.org/2001/XMLSchema#string

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings

about

P2860

P2860

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P5875

P698

P932